Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2011

01-10-2011 | Translational Research and Biomarkers

Contrasting Prognostic Implications of Platelet-Derived Growth Factor Receptor-β and Vascular Endothelial Growth Factor Receptor-2 in Patients with Angiosarcoma

Authors: Kan Yonemori, MD, Koji Tsuta, MD, PhD, Masashi Ando, MD, Akihiro Hirakawa, MS, Yutaka Hatanaka, PhD, Yoshihiro Matsuno, MD, PhD, Hirokazu Chuman, MD, Naoya Yamazaki, MD, Yasuhiro Fujiwara, MD, PhD, Tadashi Hasegawa, MD, PhD

Published in: Annals of Surgical Oncology | Issue 10/2011

Login to get access

Abstract

Background

Angiosarcoma is an extremely rare tumor among sarcomas and comprises a heterogeneous group of high-grade vascular malignancies. Our study aimed to examine the correlations between 6 immunohistochemical biomarkers—stem cell factor receptor (KIT), platelet-derived growth factor receptor (PDGFR)-α, PDGFR-β, vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, and VEGFR-3—and overall survival (OS) in patients with angiosarcomas.

Methods

Immunohistochemical analyses for the 6 biomarkers were performed by using tumor specimens obtained from 34 patients with angiosarcomas. Correlations between biomarkers were examined by Fisher’s exact test. For each biomarker, the correlation between the immunohistochemical score and OS was examined by the log-rank test and Cox regression analysis.

Results

The percentages of angiosarcoma patients with positive expressions (immunohistochemical score > 0) of KIT, PDGFR-α, PDGFR-β, VEGFR-1, VEGFR-2, and VEGFR-3 were 14.7%, 11.8%, 88.2%, 61.8%, 94.1%, and 100.0%, respectively. No statistically significant correlations between any 2 biomarkers were observed. Cox regression analysis demonstrated a significant positive correlation between short OS and the immunohistochemical score for PDGFR-β and between long OS and the immunohistochemical score for VEGFR-2.

Conclusion

Increased expression of PDGFR-β may be a statistically significant prognostic factor for poor OS, while increased expression of VEGFR-2 may be a favorable prognostic factor for patients with angiosarcoma.
Literature
1.
Naka N, Ohsawa M, Tomita Y, et al. Prognostic factors in angiosarcoma: multivariate analysis of 55 cases. J Surg Oncol. 1996;61:170–6.PubMedCrossRef
2.
Otis CN, Peschel R, McKhann C, Merino MJ, Duray PH. The rapid onset of cutaneous angiosarcoma after radiotherapy for breast carcinoma. Cancer. 1986;57:2130–4.PubMedCrossRef
3.
Benda JA, Al-Jurf AS, Benson AB III. Angiosarcoma of the breast following segmental mastectomy complicated by lymphedema. Am J Clin Pathol. 1987;87:651–5.PubMed
4.
Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007;18:2030–6.PubMedCrossRef
5.
Lahat G, Dhuka AR, Hallevi H, et al. Angiosarcoma: clinical and molecular insights. Ann Surg. 2010;251:1098–106.PubMedCrossRef
6.
Verweij J, Baker LH. Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. Eur J Cancer. 2010;46:863–8.PubMedCrossRef
7.
Ordóñez JL, Martins AS, Osuna D, Madoz-Gurpide J, de Alava E. Targeting sarcomas: therapeutic targets and their rational. Semin Diagn Pathol. 2008;25:304–16.PubMedCrossRef
8.
Behrens C, Lin HY, Lee JJ, et al. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Can Res. 2008;14:6014–22.CrossRef
9.
Shet T, Malaviya A, Nadkarni M, et al. Primary angiosarcoma of the breast: observations in Asian Indian women. J Surg Oncol. 2006;94:368–74.PubMedCrossRef
10.
Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol. 2002;117:188–93.PubMedCrossRef
11.
Komdeur R, Hoekstra HJ, Molenaar WM, et al. Clinicopathologic assessment of postradiation sarcomas: KIT as a potential treatment target. Clin Cancer Res. 2003;9:2926–32.PubMed
12.
Miettinen M, Sarlomo-Rikala M, Lasota J. KIT expression in angiosarcomas and fetal endothelial cells: lack of mutations of exon 11 and exon 17 of C-kit. Mod Pathol. 2000;13:536–41.PubMedCrossRef
13.
Palman C, Bowen-Pope DF, Brooks JJ. Platelet-derived growth factor receptor (beta-subunit) immunoreactivity in soft tissue tumors. Lab Invest. 1992;66:108–15.PubMed
14.
Itakura E, Yamamoto, H, Oda Y, et al. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol. 2008;97:74–81.PubMedCrossRef
15.
Tokuyama W, Mikami T, Masuzawa M, Okayasu I. Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face. Hum Pathol. 2010;41:407–14.PubMedCrossRef
16.
Stacher E, Gruber-Mösenbacher U, Halbwedl I, et al. The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas: new potential therapeutic targets? Lung Cancer. 2009;65:49–55.PubMedCrossRef
17.
Hashimoto M, Ohsawa M, Ohnishi A, et al. Expression of vascular endothelial growth factor and its receptor mRNA in angiosarcoma. Lab Invest. 1995;73:859–63.PubMed
18.
Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer. 1999;86:2606–12.CrossRef
19.
Folpe AL, Veikkola T, Valtola R, Weiss SW. Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi’s sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol. 2000;13:180–5.PubMedCrossRef
20.
Ghosh S, Sullivan CA, Zerkowski MP, et al. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol. 2008;39:1835–43.PubMedCrossRef
21.
Okita NT, Yamada Y, Takahari D, et al. Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer. Jpn J Clin Oncol. 2009;39:595–600.PubMedCrossRef
22.
Carrillo de Santa Pau E, Arias FC, Caso Peláez E et al (2009) Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer. 115:1701–12.PubMedCrossRef
23.
Amo Y, Masuzawa M, Hamada Y, Katsuoka K. Serum concentrations of vascular endothelial growth factor-D in angiosarcoma patients. Br J Dermatol. 2004;150:160–1.PubMedCrossRef
24.
Kubo T, Piperdi S, Rosenblum J, Antonescu CR, et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer. 2008;112:2119–29.PubMedCrossRef
25.
Uren A, Merchant MS, Sun CJ, et al. Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing’s sarcoma cells. Oncogene. 2003;22:2334–42.PubMedCrossRef
26.
Sulzbacher I, Birner P, Trieb K, Muhlbauer M, Lang S, Chott A. Platelet-derived growth factor-alpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome. Am J Surg Pathol. 2001;25:1520–7.PubMedCrossRef
27.
Penel N, Bui BN, Bay JO, Cupissol D, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26:5269–74.PubMedCrossRef
28.
Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2:1843–49.PubMed
29.
Maki RG, D’Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133–40.PubMedCrossRef
30.
Kumar R, Crouthamel MC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer. 2009;101:1717–23.PubMedCrossRef
31.
Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009;69:7175–9.PubMedCrossRef
Metadata
Title
Contrasting Prognostic Implications of Platelet-Derived Growth Factor Receptor-β and Vascular Endothelial Growth Factor Receptor-2 in Patients with Angiosarcoma
Authors
Kan Yonemori, MD
Koji Tsuta, MD, PhD
Masashi Ando, MD
Akihiro Hirakawa, MS
Yutaka Hatanaka, PhD
Yoshihiro Matsuno, MD, PhD
Hirokazu Chuman, MD
Naoya Yamazaki, MD
Yasuhiro Fujiwara, MD, PhD
Tadashi Hasegawa, MD, PhD
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1640-4

Other articles of this Issue 10/2011

Annals of Surgical Oncology 10/2011 Go to the issue

Melanomas

Selective Sentinel Lymph Node Dissection for Melanoma: Importance of Harvesting Nodes with Lower Radioactive Counts without the Need for Blue Dye

Breast Oncology

Identifying Gaps in the Locoregional Management of Early Breast Cancer: Highlights from the Kyoto Consensus Conference

Head and Neck Oncology

Low-Dose Preoperative Chemoradiation Therapy Compared with Surgery Alone with or Without Postoperative Radiotherapy in Patients with Head and Neck Carcinoma

Head and Neck Oncology

Long-Term Experience in Sentinel Node Biopsy for Early Oral and Oropharyngeal Squamous Cell Carcinoma

Healthcare Policy and Outcomes

Intraoperative Epidural Analgesia Prevents the Early Proinflammatory Response to Surgical Trauma. Results from a Prospective Randomized Clinical Trial of Intraoperative Epidural Versus General Analgesia

Breast Oncology

Ductal Carcinoma-In-Situ of the Breast with Subsequent Distant Metastasis and Death